In:
BMC Biotechnology, Springer Science and Business Media LLC, Vol. 23, No. 1 ( 2023-10-03)
Abstract:
The major safety concern of the clinical application of wild type FGF19 (FGF19 WT ) emerges given that its extended treatment causes hepatocellular carcinoma. Therefore, we previously generated a safer FGF19 variant - FGF19 ΔKLB , which have same effects on glycemic control and bile acid production but much less mitogenic activity. However, it remains unclear as to whether FGF19 ΔKLB ameliorates intrahepatic cholestasis. Results We found that, similar to that of FGF19 WT , the chronic administration of FGF19 ΔKLB protects mice from cholestatic liver injury in these two models. The therapeutic benefits of FGF19 ΔKLB on cholestatic liver damage are attributable, according to the following mechanistic investigation, to the reduction of BA production, liver inflammation, and fibrosis. More importantly, FGF19 ΔKLB did not induce any tumorigenesis effects during its prolonged treatment. Conclusions Together, our findings raise hope that FGF19 ΔKLB may represent a useful therapeutic strategy for the treatment of intrahepatic cholestasis.
Type of Medium:
Online Resource
ISSN:
1472-6750
DOI:
10.1186/s12896-023-00810-9
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2023
detail.hit.zdb_id:
2052746-9
SSG:
12
Permalink